Mirati Therapeutics (NASDAQ:MRTX): The stock price is expected to reach $ 22.83 in the short term. The number of analysts agreeing with this consensus is 6. The higher estimate for the short term price target is at $32 while the lower estimate is at $14. The standard deviation of the price stands at $6.91.
Many analysts have stated their opinion on the company shares. Equity Analysts at the Brokerage Firm, Citigroup, maintains their rating on the shares of Mirati Therapeutics (NASDAQ:MRTX). Citigroup has a Buy rating on the shares. As per the latest research report, the brokerage house lowers the price target to $23 per share from a prior target of $30. The rating by the firm was issued on June 6, 2016. For the current week, the company shares have a recommendation consensus of Buy.
On the companys insider trading activities, The Securities and Exchange Commission has divulged that Gergen Mark J, officer (Executive VP, COO) of Mirati Therapeutics, Inc., had unloaded 10,000 shares at an average price of $25.92 in a transaction dated on January 15, 2016. The total value of the transaction was worth $259,200.
Mirati Therapeutics (NASDAQ:MRTX) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.62 points or 7.66% at $7.47 with 1,135,432 shares getting traded. Post opening the session at $8, the shares hit an intraday low of $7.3 and an intraday high of $8.09 and the price was in this range throughout the day. The company has a market cap of $149 million and the number of outstanding shares have been calculated to be 19,906,776 shares. The 52-week high of Mirati Therapeutics (NASDAQ:MRTX) is $52 and the 52-week low is $7.3.